Partnerships

St. George's University and UAE school group Taaleem have signed an MoU giving eligible students access to MD admissions pathways and up to USD

Assembly Biosciences will take a 40% share of US costs and profits for the GS-1179 helicase-primase inhibitor as a Phase 2 trial approaches.

Dual PDE3/4 inhibitor AN01 improved lung function versus placebo in COPD patients already on bronchodilator therapy, with data presented at ERS 2026.

Novartis has dosed its first Sjögren's disease patient with MRT-6160, triggering a $50m payment to Monte Rosa under the pair's $2.1bn

Lakeland's Hong Kong subsidiary has secured a follow-on contract to supply flame-resistant foul weather suits to Hong Kong Government Flying Service pilots

Nokia's Network as Code platform replaces SMS one-time passcodes for BeeHealthy, a white-label health SaaS serving providers across Europe and the Middle

Vivos Inc. has validated its PrecisionGel polymer platform in an Elsevier journal, supporting clinical programmes at Mayo Clinic and licensing talks with pharmaceutical

NorthStrive Biosciences will test probiotic candidates EL-22 and EL-32 in a live-mouse microgravity study under a non-binding deal with Australia's

A late-stage development advance in Centessa's OX2R agonist pipeline triggers an $8.6 million payment to Nxera, which retains future milestone and royalty

NorthStrive Biosciences has formalised a six-month expansion programme to narrow four AI-discovered mitochondrial compounds toward a lead nomination in cardiac disease

Lumexa Imaging swung to a $2.7m net profit in Q2 2026 as advanced imaging volumes grew 6.8% and the company added its ninth

IBA will co-lead end-of-life and waste-management work in a 91-partner EU initiative targeting PFAS removal from healthcare and pharmaceutical waste

Kala Bio will be the sole US distributor of Virotek's ophthalmology genomic testing programme under a one-year deal effective 4 September 2026.

BioStem Technologies has secured GPO contract coverage for VENDAJE and VENDAJE AC through Vizient and Premier, opening hospital access for the first time.

The Paris-based robotics firm said blue-chip automotive, logistics and healthcare operators are among early adopters of its Calvin-40 humanoid robot.

China's NMPA has approved Eisai and Biogen's once-weekly lecanemab SC formulation for early Alzheimer's, making China the second market globally to

GSK gains worldwide rights outside Greater China to HMPL-A830, a novel antibody-targeted therapy conjugate, with $110m upfront and up to $1.295bn in

Kala Bio will market Virotek's CLIA-registered ophthalmology genetic screening programme across U.S. eye care practices, targeting a definitive deal within 30 days.

Alvotech's BLA for AVT80, a proposed interchangeable subcutaneous biosimilar to Entyvio, has been accepted for review by the FDA, completing its dual-presentation

The Hong Kong-listed platform reported RMB 1.82bn in H1 2026 revenue, driven by its proprietary XingShi LLM and a fast-growing chronic disease